OR WAIT 15 SECS
Dassault Systèmes, a provider of virtual universes to imagine sustainable innovations, has signed a definitive agreement to acquire Medidata Solutions in an all-cash transaction.
Dassault Systèmes, a provider of virtual universes to imagine sustainable innovations, has signed a definitive agreement to acquire Medidata Solutions in an all-cash transaction, it was announced in a June 12, 2019 press release.
The acquisition will be made at a price of $92.25 per share of Medidata, which represents an enterprise value of $5.8 billion, and will incorporate the company along with all its clinical and commercial solutions. Both company boards unanimously approved the acquisition agreement.
“Today marks a significant milestone for the life-sciences industry and the value of the virtual world to address the complexity of developing personalized medicine and patient-centric experiences. Multidiscipline scientific innovation and industrial performance call for a platform approach connecting the dots between people, ideas, and data,” said Bernard Charlès, vice chairman and CEO, Dassault Systèmes, in the release. “Medidata’s leading position in clinical trials complements our life-sciences solutions on the 3DEXPERIENCE collaborative platform. Medidata’s recent expansion into real-world evidence and analytics coupled with the power of modeling and simulation demonstrates how the virtual world will catalyze the next generation of patient-inclusive therapeutics. We are now well positioned to be the enabler of the life-sciences industry transformation, illustrating our company’s purpose of harmonizing product, nature, and life.”
“Our mission to get the right treatment, to the right patient, at the right time has fueled our 20-year journey of innovation and commitment to the life-sciences industry,” added Tarek Sherif, co-founder, chairman, and CEO, Medidata. “We share common vision, values, and passion with Dassault Systèmes, and our combined talents will empower the life-sciences industry with an end-to-end business platform.”
“Facilitating new therapeutic innovations to become the next standards of care has been our commitment since day one,” said Glen de Vries, co-founder and president, Medidata. “Ultimately, we will unlock enormous opportunities for our customers and patients, advancing life sciences in the age of precision medicine.”